Oxford Immunotec Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for February 28, 2017
(Thomson Reuters ONE) -
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) --
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics
company focused on developing and commercializing proprietary tests for the
management of underserved immune-regulated conditions, today announced that it
plans to release fourth quarter and full year 2016 financial results after the
close of the market on Tuesday, February 28, 2017. Dr. Peter Wrighton-Smith,
Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a
conference call to review the Company's results at 5:00 p.m. Eastern Time the
same day. The call will be concurrently webcast.
To listen to the conference call on your telephone, please dial (855) 363-5047
for United States callers and +1 (484) 365-2897 for international callers and
reference confirmation code 59419141, approximately ten minutes prior to start
time. To access the live audio webcast or subsequent archived recording, visit
the Investor Relations section of Oxford Immunotec's website
at www.oxfordimmunotec.com. The replay will be available on the Company's
website for approximately 60 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused
on developing and commercializing proprietary tests for the management of
underserved immune-regulated conditions. The Company's first product is the T-
SPOT(®).TB test, which is used to test for tuberculosis infection. The T-
SPOT.TB test has been approved for sale in over 50 countries, including the
United States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The company's second product line is a range of assays for tick-borne
diseases, such as Lyme disease, obtained through the acquisitions of Imugen and
Immunetics. The T-SPOT.CMV test and the T-SPOT.PRT test are part of the
Company's third product line focused on the transplantation market. In addition
to these three product lines, the Company has additional active development
programs in other immune-regulated conditions. The Company is headquartered near
Oxford, U.K. and in Marlborough, Mass. Additional information can be found
at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
Immunetics is a trademark of Immunetics, Inc.
CONTACTS:
For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley(at)oxfordimmunotec.com
For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
raltieri(at)oxfordimmunotec.com
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501
oxfordimmunotec(at)westwicke.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 14.02.2017 - 22:05 Uhr
Sprache: Deutsch
News-ID 524180
Anzahl Zeichen: 3528
contact information:
Town:
Oxfordshire
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 164 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Oxford Immunotec Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for February 28, 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Oxford Immunotec (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
